Ann: Mx1 - Amended Auditor's Report, page-3

Are you referring to the pararaph added?

This is not uncommon with companies in the discovery, development or commercialisation phases. I would presume the change from last year is the timing of a CR, and the reduced cash balance the company has.

I think there will be a small CR soon to remove this concern, then hopefully sales from the new unit and argus can give SP appreciation and cashflows for a higher CR or debt to get them through to profitability.

I will buy back in on the CR, with increases as milestones are hit.

All IMO, DYOR.